Catalent Inc
NYSE:CTLT
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
37.18
60.98
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Catalent Inc
Catalent Inc
Net Change in Cash
Catalent Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Catalent Inc
NYSE:CTLT
|
Net Change in Cash
$126m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Change in Cash
$252m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Change in Cash
$325m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-58%
|
CAGR 10-Years
-20%
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Change in Cash
-$1.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Change in Cash
$6B
|
CAGR 3-Years
31%
|
CAGR 5-Years
169%
|
CAGR 10-Years
N/A
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Change in Cash
$988.2m
|
CAGR 3-Years
72%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Catalent Inc
Glance View
Catalent Inc. is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for pharmaceuticals, biologics, and consumer health products. Founded in 2007, the company has rapidly grown its footprint by offering innovative solutions that enhance drug formulation and accelerate time to market. With a portfolio that spans from drug development to commercialization, Catalent’s core mission is to improve patient outcomes by ensuring that life-changing therapies reach those who need them. The company operates state-of-the-art manufacturing facilities across the globe, fostering strong partnerships with both small biotechnology firms and large pharmaceutical corporations to optimize their products and processes. As an investor, understanding Catalent's strategic direction is vital. The company capitalizes on the booming demand for biopharmaceuticals and personalized medicines, driven by trends in population aging and the ongoing need for advanced therapeutics. Catalent's commitment to research and innovation is evidenced by its robust R&D investments and a diverse range of proprietary technologies, such as its softgel and Zydis® orally disintegrating tablet technologies. Furthermore, the company's recent expansions and acquisitions signal a strategic focus on enhancing capacity and capabilities, positioning it well to thrive in a highly competitive market. By leveraging its extensive expertise and global scale, Catalent aims not only to enhance its service offerings but to deliver sustained value to its shareholders, making it a compelling option for those seeking exposure to the dynamic healthcare sector.
See Also
What is Catalent Inc's Net Change in Cash?
Net Change in Cash
126m
USD
Based on the financial report for Sep 30, 2024, Catalent Inc's Net Change in Cash amounts to 126m USD.
What is Catalent Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
-49%
The average annual Net Change in Cash growth rates for Catalent Inc have been -49% over the past three years .
You don't have any saved screeners yet
